CONFERENCE SPONSORS
Platinum Level Sponsors
About Chiesi Global Rare Diseases
Chiesi Global Rare Diseases is a business unit of the Chiesi Group established in February 2020 and focused on research and development of treatments for rare and ultra-rare disorders. Chiesi Global Rare Diseases works in collaboration with Chiesi Group to harness the full resources and capabilities of our global network to bring innovative new treatment options to people living with rare diseases, many of whom have limited or no treatments available.
About Chiesi Group
Based in Parma, Italy, Chiesi is an international research-focused pharmaceuticals and healthcare group with over 85 years’ experience, operating in 30 countries with more than 6,000 employees. The Group is committed make innovative therapeutic solutions available in the respiratory therapeutics, specialist medicine, and rare disease areas. The Group’s R&D centre is based in Parma and works alongside 6 other important R&D hubs. In 2018 Chiesi has changed its legal status to a Benefit Corporation. Since 2019, Chiesi has been the world’s largest B Corp certified pharmaceutical group.
Gold Level Sponsors
Advancing gene therapy for neurodegenerative ophtalmic diseases
Our mission
At GenSight, our goal is to develop cutting-edge gene therapy-based treatments for people with neuro-ophtalmic diseases. Our research has initially focused on solutions for severe inherited retinal diseases. In the longer term, we hope to find solutions for people living with other neurodegenerative diseases.
Our pipeline
Our focus is on solutions for severe inherited retinal diseases that have limited treatment options and are associated with significant unmet need.
Building on years of gene therapy research, GenSight is advancing the treatment approach by harnessing the power of its proprietary Mitochondrial Targeting Sequence (MTS) platform as well as using optogenetics and other ground-breaking technologies, to develop treatment options for people living with neurodegenerative ophtalmic conditions.
A cutting-edge innovation
Our proprietary Mitochondrial Targeting Sequence (MTS) platform advance the standard of gene therapy by enabling mRNA translation and cotranslocation of key proteins into the mitochondria (1), unlocking the capacity to potentially treat a variety of mitochondrial neurodegenerative ophtalmic diseases.
1. Gray R, et al.
Allotopic Expression of Mitochondrial ATP Synthase Genes in Nucleus of Saccharomyces
cerevisiae. Methods Enzymol. 1996;264:369–389.
2022-NPM-E-002
Silver Level Sponsors
Heidelberg Engineering
Heidelberg Engineering continuously optimises imaging and healthcare IT technologies to provide ophthalmic diagnostic solutions that empower clinicians to improve patient care. At the heart of the company is the SPECTRALIS: an ophthalmic imaging platform with an upgradable, modular design. The platform allows clinicians to configure each SPECTRALIS to the specific diagnostic workflow in the practice or clinic. Multimodal imaging options include: OCT, Nsite neurology package, premium glaucoma package, widefield, autofluorescence, and anterior segment imaging.
Bronze Level Sponsors
Contact us
Great Hall, Aston Webb Building, University of Birmingham, Edgbaston, Birmingham, West Midlands B15 2TT
E: academic.conferences@contacts.bham.ac.uk